# K160983: Kyphon HV-R Bone Cement

- Pathway: 510(k) (Traditional)
- Applicant: Medtronic, Inc.
- Decided: Aug 24, 2016 after 139 days
- Product code: NDN (Cement, Bone, Vertebroplasty)
- Device class: 2
- Regulation: 21 CFR 888.3027
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 7 generations back to K002652 (2001). 10 ancestors in all.
52 later devices descend from it; 1 cites it directly.
0 of 63 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K150460: KYPHON (R) HV-R (R) Bone Cement, Medtronic Sofamor Danck USA, Inc. (2015) Summary page 4.
- K151227: KYPHON XPEDE Bone Cement, Medtronic (2015) Summary page 4.

## Most influential descendants
- K180700: KYPHON HV-R Bone Cement (2018), 51 descendants of its own
- K191148: Medtronic HV-R™ Bone Cement, Kyphon™ Xpede™ Bone Cement, CD Horizon™ Fenestrated Screw Set (2019), 50 descendants of its own
- K193011: CD Horizon™ Fenestrated Screw Set (2020), 41 descendants of its own
- K201362: CD Horizon™ Fenestrated Screw Set, CD Horizon™ Spinal System, Kyphon™ HV-R™ Bone Cement (2020), 38 descendants of its own
- K210637: CD Horizon™ Spinal System (2021), 34 descendants of its own

## Indications for use
Kyphon® HV-R® Bone Cement is indicated for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer, or benign lesions using a cementoplasty (i.e. kyphoplasty or vertebroplasty) procedure. Cancer includes multiple myeloma and metastatic lesions, including those arising from breast or lung cancer, or lymphoma. Benign lesions include hemangioma and giant cell tumor. Pathologic fracture may include a symptomatic vertebral body microfracture (as documented by appropriate imaging and/or presence of a lytic lesion) without obvious loss of vertebral body height.

Source page: https://510kreport.com/device/K160983
Methodology: https://510kreport.com/methodology